GENERAL COMMENTS
Thank you for the opportunity to review "Pharmacists" Response to Anaphylaxis in the Community (PRAC): A randomized simulated patient study of pharmacist practice". In this manuscript the authors describe a study looking at pharmacists" preparedness and engagement in treating acute anaphylaxis using simulated patient scenarios. The results showed that pharmacists were knowledgeable about anaphylaxis and emergency care, but showed poor auto-injector technique. Overall the manuscript is very well written, comprehensive and flows nicely. The topic is of interest as there is very little published looking at pharmacist"s involvement and practice with acute anaphylaxis.
Abstract:
Objective -what is meant by "everyday management"?
Methods:
Was ethics received to do the study? The authors mention in the discussion that "did not seek ethics approval" to use audio/video recordings however, normally would require ethics approval to do a simulated patient study. Could the authors elaborate?
Sample size was not conducted a-priori (power calculations done post-hoc) but was there a reason that the initial sample of 300 pharmacies chosen? Was it just a convenience sample of 100 pharmacies for each of the 3 scenarios?
How was "busyness" defined? It is not clear in the methods -how was the ratio of customers to staff identified? Was it customers waiting around the pharmacy for prescriptions or just customers in store?
Results:
Page 10, Line 58 -"preparedness score was 2.39 (1.17)" -is the 1.17 in brackets standard deviation? Please indicate as such. Also on page 11, line 23 for mean anaphylaxis score. Table 3 (though definitely visually appealing in graph format -will leave with editors to decide).
Discussion:
Page 13, line 7 -may want to be specific that the "more comprehensive discussion with the patient" is specific to engaging in discussion about anaphylaxis (sounds a bit "general" in this paragraph) Limitation -would the use of researchers to play simulated patients (vs hiring actors) be considered a potential limitation as well (ie if the researcher is tied to the research -could there be bias in their interpretation of the pharmacists responses?)
Limitations -line 50 -52 -"Although pharmacists performed better overall using the new-look Epipen, this effect may have been confounded by features…etc". How would this effect been confounded by these features unique to the simulated patients (were not the scenarios the same other than the autoinjector used? Did one researcher who acted as the simulated patient perform the scenario with only one type of autoinjector?)
VERSION 1 -AUTHOR RESPONSE

Comments from Reviewer 1 Action Taken
The keywords in the title page are different from the keywords in the article description page Keywords amended.
Line 40 page 4: it will be useful to know in which country this survey was performed (ref 19) Reference 19 is a perspective paper from the Journal of Allergy and Clinical Immunology (the journal for the American Academy of Allergy, Asthma and Immunology). It is intended to support the need for regular prescription of adrenaline autoinjectors for patients at risk of anaphylaxis. We have added reference 9 as a North American survey to support poor patient understanding of adrenaline autoinjector devices.
Line 59 page 4 needs a reference for the statement that there is anecdotal evidence that some patients choose to attend their local pharmacy instead
By the nature of anecdotal evidence, this statement is difficult to reference. Our anecdotal evidence refers to that provided directly, for example, in discussion groups, by patients or their families, or through discussion with allergy specialists. As practitioners, we are hearing more often that patients consider pharmacy a treatment destination for anaphylaxis, and this is especially true in the patient that does not recognise their symptoms as anaphylaxis. The sentences following line 59 page 4 explain this further.
Line 11 page 5 change "role" to "roles" Amended.
Line 35 page 5 purpose of study (i) consider changing to "their preparedness for acute anaphylaxis management"
Thank you for the comment. We have classified anaphylaxis management as (1) first aid for the acute patient and (2) discussion/advice for the non-acute patient. We prefer to retain aim (i) as written to avoid confusion with the term "management" (as methods and results consider "management" as both items 1 and 2, and aim (i) refers only to item 1.)
In Methods section please provide a brief description of the three researchers Added to methods section under Scenario.
Page 8 reports that the Scenario Pilot involved a random sample of 9 pharmacies. Were these 9 pharmacies excluded from the 310 pharmacies as the pharmacists would have been familiar with the research? If they were excluded then why not select all 301
Thank you for your question. We planned to include the 9 pharmacies selected for the pilot in the final analysis. However, as there were modifications to the data collection tool after the pilot, it was not appropriate to include them in this analysis.
pharmacies for participation (310-9)?
The Results section report 271 visits but there is no explanation of the 29 visits that are not reported.
The 29 visits not included in the final analysis are shown in Figure 1 , which represents the study flow. This Figure states reasons for exclusion. In the interests of brevity, these reasons were not written again in the Results section.
Comments from Reviewer 2 Action Taken Abstract
Thank you for this useful comment. We have amended the phrasing to better reflect the objective.
Methods
Was ethics received to do the study?
The authors mention in the discussion that "did not seek ethics approval" to use audio/video recordings however, normally would require ethics approval to do a simulated patient study. Could the authors elaborate?
Approval to conduct the study was received by the University of Western Australia Human Research Ethics Committee. A statement of this is included in the original submission, page 18, line 26.
Sample size was not conducted apriori (power calculations done posthoc) but was there a reason that the initial sample of 300 pharmacies chosen? Was it just a convenience sample of 100 pharmacies for each of the 3 scenarios?
Thank you for this question. We considered cost (to purchase antihistamines, actor fees) and time required/available to conduct pharmacy visits before deciding on the sample size. We elected to randomise 100 pharmacies per device based on these considerations.
The ratio represented all customers in store to all pharmacy staff. We believe this better reflects how busy the pharmacist may have been (whether filling prescriptions or assisting with queries at the counter) as pharmacy staff may be drawn to customers in store, increasing the workload at the counter. We have amended this definition for clarity (in Analysis methods).
Results
Page 10, Line 58 -"preparedness score was 2.39 (1.17)" -is the 1.17 in brackets standard deviation? Please indicate as such. Also on page 11, line 23 for mean anaphylaxis score.
Yes, this represents standard deviation. We have amended both results.
Figure 2 seems like a repeat of information in Table 3 (though definitely visually appealing in graph Thank you for this comment. Figure 2 graphs the sections of Table 3 that are specifically relevant to the aim. We recognise not all readers will thoroughly read the Table, and consider format -will leave with editors to decide).
most will be drawn to the Figure. Thus we believe Figure 2 is important for the rapid reader to quickly see the strengths and weaknesses in pharmacist practice with anaphylaxis patients.
Discussion
Page 13, line 7 -may want to be specific that the "more comprehensive discussion with the patient" is specific to engaging in discussion about anaphylaxis (sounds a bit "general" in this paragraph)
We appreciate this comment. Sentence amended to be more specific.
Limitation -would the use of researchers to play simulated patients (vs hiring actors) be considered a potential limitation as well (ie if the researcher is tied to the research -could there be bias in their interpretation of the pharmacists responses?
This is an interesting consideration. We used two researchers and an actor as our data collectors. We have considered recall bias and the potential for different "memory" of the encounter based on the simulated patient, as limitations. Participant bias due to intrinsic involvement in the research is unlikely as participants performed better in general with the New-look EpiPen (assessed by a researcher) compared to Original EpiPen and Anapen (assessed by a researcher and an actor respectively).
Thank you for your question. Yes, the scenario was defined and unchanged across the three simulated patients. Each researcher used only one type of autoinjector in every one of their visits.
However, we consider that as our three researchers were different people, with different ages, gender, appearance and personalities, it is possible that pharmacist reactions (such as willingness to demonstrate, or general empathy and the effect this may have on extended discussion) to these people could vary simply because they were different. It is also possible the simulated patients may have different recall abilities and we did not assess this. In the interests of brevity we have not changed the wording in this section, however we have included a small description of the three researchers in the Methods section, allowing the reader to recognise the difference between them.
